BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22927297)

  • 41. Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers.
    Svrcek M; Buhard O; Colas C; Coulet F; Dumont S; Massaoudi I; Lamri A; Hamelin R; Cosnes J; Oliveira C; Seruca R; Gaub MP; Legrain M; Collura A; Lascols O; Tiret E; Fléjou JF; Duval A
    Gut; 2010 Nov; 59(11):1516-26. PubMed ID: 20947886
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.
    Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A
    Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer.
    Luo Y; Wong CJ; Kaz AM; Dzieciatkowski S; Carter KT; Morris SM; Wang J; Willis JE; Makar KW; Ulrich CM; Lutterbaugh JD; Shrubsole MJ; Zheng W; Markowitz SD; Grady WM
    Gastroenterology; 2014 Aug; 147(2):418-29.e8. PubMed ID: 24793120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer.
    Gu S; Lin S; Ye D; Qian S; Jiang D; Zhang X; Li Q; Yang J; Ying X; Li Z; Tang M; Wang J; Jin M; Chen K
    Clin Epigenetics; 2019 Mar; 11(1):41. PubMed ID: 30846004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular subtyping of colorectal cancer: time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome.
    Fearon ER; Carethers JM
    Gastroenterology; 2015 Jan; 148(1):10-3. PubMed ID: 25451650
    [No Abstract]   [Full Text] [Related]  

  • 46. Similarities of molecular genetic changes in synchronous and metachronous colorectal cancers are limited and related to the cancers' proximities to each other.
    Zauber P; Huang J; Sabbath-Solitare M; Marotta S
    J Mol Diagn; 2013 Sep; 15(5):652-60. PubMed ID: 23810502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers.
    Vedeld HM; Andresen K; Eilertsen IA; Nesbakken A; Seruca R; Gladhaug IP; Thiis-Evensen E; Rognum TO; Boberg KM; Lind GE
    Int J Cancer; 2015 Feb; 136(4):844-53. PubMed ID: 24948044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic and Prognostic Value of
    Picardo F; Romanelli A; Muinelo-Romay L; Mazza T; Fusilli C; Parrella P; Barbazán J; Lopez-López R; Barbano R; De Robertis M; Taffon C; Bordoni V; Agrati C; Costantini M; Ricci F; Graziano P; Maiello E; Muscarella LA; Fazio VM; Poeta ML
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635093
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples.
    Barták BK; Kalmár A; Péterfia B; Patai ÁV; Galamb O; Valcz G; Spisák S; Wichmann B; Nagy ZB; Tóth K; Tulassay Z; Igaz P; Molnár B
    Epigenetics; 2017 Sep; 12(9):751-763. PubMed ID: 28753106
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.
    Perez-Carbonell L; Balaguer F; Toiyama Y; Egoavil C; Rojas E; Guarinos C; Andreu M; Llor X; Castells A; Jover R; Boland CR; Goel A
    PLoS One; 2014; 9(8):e104285. PubMed ID: 25127039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aberrant hypermethylation of OGDHL gene promoter in sporadic colorectal cancer.
    Khalaj-Kondori M; Hosseinnejad M; Hosseinzadeh A; Behroz Sharif S; Hashemzadeh S
    Curr Probl Cancer; 2020 Feb; 44(1):100471. PubMed ID: 30904169
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer.
    Øster B; Linnet L; Christensen LL; Thorsen K; Ongen H; Dermitzakis ET; Sandoval J; Moran S; Esteller M; Hansen TF; Lamy P; ; Laurberg S; Ørntoft TF; Andersen CL
    Int J Cancer; 2013 May; 132(10):2303-15. PubMed ID: 23115050
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Frequent epigenetic silencing of the folate-metabolising gene cystathionine-beta-synthase in gastrointestinal cancer.
    Zhao H; Li Q; Wang J; Su X; Ng KM; Qiu T; Shan L; Ling Y; Wang L; Cai J; Ying J
    PLoS One; 2012; 7(11):e49683. PubMed ID: 23152928
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of MSX1 and DCLK1 as mRNA Biomarkers for Colorectal Cancer Detection Through DNA Methylation Information.
    Sun AJ; Gao HB; Liu G; Ge HF; Ke ZP; Li S
    J Cell Physiol; 2017 Jul; 232(7):1879-1884. PubMed ID: 27966796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
    Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
    Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of Methylation Profiles of Cancer-related Genes in Circulating Tumor Cells Population.
    Lyberopoulou A; Galanopoulos M; Aravantinos G; Theodoropoulos GE; Marinos E; Efstathopoulos EP; Gazouli M
    Anticancer Res; 2017 Mar; 37(3):1105-1112. PubMed ID: 28314271
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Promoter hypomethylation of RAR-related orphan receptor α 1 is correlated with unfavorable clinicopathological features in patients with colorectal cancer.
    Kano H; Takayama T; Midorikawa Y; Nagase H
    Biosci Trends; 2016 Jul; 10(3):202-9. PubMed ID: 27301432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How the lab is changing our view of colorectal cancer.
    Cremolini C; Pietrantonio F
    Tumori; 2016 Dec; 102(6):541-547. PubMed ID: 27647226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Promoter hypermethylation inactivate tumor suppressor FAM134B and is associated with poor prognosis in colorectal cancer.
    Islam F; Gopalan V; Pillai S; Lu CT; Kasem K; Lam AK
    Genes Chromosomes Cancer; 2018 May; 57(5):240-251. PubMed ID: 29318692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas.
    Lind GE; Danielsen SA; Ahlquist T; Merok MA; Andresen K; Skotheim RI; Hektoen M; Rognum TO; Meling GI; Hoff G; Bretthauer M; Thiis-Evensen E; Nesbakken A; Lothe RA
    Mol Cancer; 2011 Jul; 10():85. PubMed ID: 21777459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.